-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Saturday, Lilly Presents Eloralintide Phase 2 Exit Interview Results, With 74% Reporting Fewer Cravings, 52% Less Food Noise, Alongside EloraTZP, Retatrutide, Zepbound And Foundayo Data At ObesityWeek 2026

Benzinga·11/16/2026 06:41:47
Listen to the news
  • Phase 2 results showed EloraTZP, an investigational combination of eloralintide and tirzepatide, delivered substantial weight loss and A1C improvements in participants with obesity and type 2 diabetes
  • Results from TRIUMPH-1, TRIUMPH-2 and TRIUMPH-4 demonstrated retatrutide, an investigational triple agonist, reduced obstructive sleep apnea severity and knee osteoarthritis pain in adults with obesity
  • People reported Foundayo was simple and easy to use in a new real-world evidence study, while patient-reported outcomes showed that participants treated with eloralintide reported reductions in food noise, food cravings and alcohol consumption